Dr. Manoj Khanna, OD Optometrist Medicare: Medicare Enrolled Practice Location: 161 Woodbridge Center Drive, Clvc, Woodbride, NJ 07095 Phone: 215-450-4239 Fax: 973-588-3941 |
News Archive
Schering-Plough Corporation has announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for SAPHRIS (asenapine) sublingual tablets in the acute treatment of schizophrenia in adults and in the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults as monotherapy.
In various states, lawmakers are concentrating on abortion or contraception bills. Meanwhile, some Texas chapters of Planned Parenthood are merging.
Ascenta Therapeutics announced today the signing of a global collaboration and licensing agreement with sanofi-aventis covering several early-stage agents being investigated for their potential to restore tumor cell apoptosis (programmed cell death). These orally-active, small-molecule drug candidates inhibit the interaction between HDM2 (Human Double Minute 2) and p53, removing a block to normal p53 tumor suppressor function and potentially enhancing cancer control and treatment.
The shorter you are- the more your risk of coronary heart disease. That's the key finding of a new study led by the University of Leicester which discovered that every 2.5 inches change in your height affected your risk of coronary heart disease by 13.5%. For example, compared to a 5ft 6inch tall person, a 5 foot tall person on average has a 32% higher risk of coronary heart disease because of their relatively shorter stature.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at Radboud University Nijmegen Medical Centre in the Netherlands announced today that they have published new pre-clinical results in the journal Cancer Immunology Immunotherapy describing the development of a dendritic cell (DC) cancer vaccine with enhanced immunogenic potential.
› Verified 8 days ago